Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Authors
Dang, NOgura, M
Castaigne, S
Fayad, L
Jerkeman, M
Radford, John A
Pezzutto, A
Bondarenko, I
Stewart, D
Shnaidman, M
Sullivan, S
Vandendries, E
Tobinai, K
Ramchandren, R
Hamlin, P
Giné, E
Ando, K
Affiliation
University of Florida, Gainesville, FL, USANagoya Daini Red Cross Hospital, Nagoya, JapanIssue Date
2017-07-05
Metadata
Show full item recordCitation
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 2017 Br J HaematolJournal
British Journal of HaematologyDOI
10.1111/bjh.14820PubMed ID
28677896Type
ArticleLanguage
enDescription
Lymphoma Research TeamISSN
1365-2141ae974a485f413a2113503eed53cd6c53
10.1111/bjh.14820
Scopus Count
Collections
Related articles
- Phase I Study of Inotuzumab Ozogamicin Combined with R-CVP for Relapsed/Refractory CD22+ B-cell Non-Hodgkin Lymphoma.
- Authors: Ogura M, Tobinai K, Hatake K, Davies A, Crump M, Ananthakrishnan R, Ishibashi T, Paccagnella ML, Boni J, Vandendries E, MacDonald D
- Issue date: 2016 Oct 1
- Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma.
- Authors: Ogura M, Hatake K, Ando K, Tobinai K, Tokushige K, Ono C, Ishibashi T, Vandendries E
- Issue date: 2012 May
- A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
- Authors: Goy A, Forero A, Wagner-Johnston N, Christopher Ehmann W, Tsai M, Hatake K, Ananthakrishnan R, Volkert A, Vandendries E, Ogura M
- Issue date: 2016 Aug
- Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab.
- Authors: Fayad L, Offner F, Smith MR, Verhoef G, Johnson P, Kaufman JL, Rohatiner A, Advani A, Foran J, Hess G, Coiffier B, Czuczman M, Giné E, Durrant S, Kneissl M, Luu KT, Hua SY, Boni J, Vandendries E, Dang NH
- Issue date: 2013 Feb 10
- Inotuzumab Ozogamicin: First Global Approval.
- Authors: Lamb YN
- Issue date: 2017 Sep